OrbiMed Advisors LLC's Form 4 filing
Damora Therapeutics, Inc. (DMRA) · filed Jul 17, 2023
- Accession no.
- 0000947871-23-000753
- Filed
- Jul 17, 2023, 4:13 PM ET
- Trade date
- Jul 13, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $467.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| OrbiMed Advisors LLCCIK 0001055951 | 10% Owner |
| OrbiMed Israel GP II, L.P.CIK 0001682090 | 10% Owner |
| OrbiMed Advisors Israel II LtdCIK 0001682093 | 10% Owner |
| OrbiMed Capital GP VII LLCCIK 0001760648 | 10% Owner |
| OrbiMed Genesis GP LLCCIK 0001808744 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 13, 2023 | Common Stock | SSaleDisposed | −9,800 | $2.40 | −$23,520 | 169,953 | Indirect | |
| Jul 13, 2023 | Common Stock | SSaleDisposed | −52,800 | $2.40 | −$126,720 | 914,267 | Indirect | |
| Jul 13, 2023 | Common Stock | SSaleDisposed | −132,100 | $2.40 | −$317,040 | 2,285,687 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.